Home/Surv Biopharma/Masaki Yamada
MY

Masaki Yamada

President

Surv Biopharma

Therapeutic Areas

Surv Biopharma Pipeline

DrugIndicationPhase
Surv.m-CRA-1Oncology (unspecified solid tumors)Phase 1
In vivo gene therapy viruses (HGF, etc.)Hepatic diseases, Diabetes mellitusPreclinical